Orakl Oncology

Cancer complexity leads to a 96% failure rate of drug candidates in clinical trials and a shortage of new treatments. Orakl Oncology’s ambition is to finally address the heterogeneity of cancer and patient specificities as early as possible in drug development.

‍

By creating a collection of avatars of patients’ tumors, they predict how each patient will respond to future drugs, combining best-in-class biology with deep clinical data and machine learning to efficiently discover and optimize new treatments for the right patients.